[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567126":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":33,"locations":41,"responsibleParty":61,"collaborators":30,"id":63,"slug":30,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":30,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":30,"enrollmentInfo":71,"targetDuration":30,"studyType":74,"phases":75,"briefSummary":67,"conditions":77,"keywords":30,"overallStatus":57,"whyStopped":30,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Jemincare","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"JMKX003002 once daily","EXPERIMENTAL","JMKX003002 once daily for 4 weeks",[13],"Drug: JMKX003002 will be administered orally",{"label":15,"type":10,"description":16,"interventionNames":17},"JMKX003002 twice daily","JMKX003002 twice daily for 4 weeks",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Sevelamer carbonate","ACTIVE_COMPARATOR","Sevelamer carbonate three times daily for 4 weeks",[23],"Drug: Sevelamer carbonate",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","JMKX003002 will be administered orally","tablets for oral administration.",[9,15],null,{"type":26,"name":19,"description":28,"armGroupLabels":32,"otherNames":30},[19],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":30,"email":38},"Jing Xu","CONTACT","0086-020-87755766","xujing2@jemincare.com",{"name":40,"role":36,"phone":37,"phoneExt":30,"email":30},"Wei Chen",[42,56],{"facility":43,"status":44,"city":45,"state":46,"zip":30,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"The First Affiliated Hospital, Sun Yat-sen University","NOT_YET_RECRUITING","Guangzhou","Guangdong","China",{"type":49,"coordinates":50},"Point",[51,52],113.25,23.11667,{"lat":52,"lon":51},[55],{"name":35,"role":36,"phone":37,"phoneExt":30,"email":38},{"facility":43,"status":57,"city":45,"state":46,"zip":30,"country":47,"cosmosGeoPoint":58,"geoPoint":60,"contacts":30},"RECRUITING",{"type":49,"coordinates":59},[51,52],{"lat":52,"lon":51},{"type":62,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100567126",false,"NCT06664125","Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia","A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia","Inclusion Criteria:\n\n1. Able to understand the procedures of this trial and provide written informed consent voluntarily;\n2. Age ≥ 18 years, male or female;\n3. On a stable hemodialysis regimen at a frequency of two or three times per week for at least 12 weeks prior to the screening visit;\n4. Serum phosphorus within the trial-required range.\n\nExclusion Criteria:\n\n1. Any history of inflammatory bowel disease or diarrheal irritable bowel syndrome;\n2. Pregnant or breastfeeding;\n3. Any history of a parathyroid intervention;\n4. Diarrhea or loose stools occurred within 1 week prior to randomization.","ALL","18 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2",[78],"Hyperphosphatemia","2025-01-31",{"date":81,"type":82},"2025-02-03","ACTUAL",{"date":84,"type":82},"2024-12-30",{"date":86,"type":73},"2025-09-30",{"name":5,"class":6},2]